Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.?Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.?Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.?ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.
| Revenue (Most Recent Fiscal Year) | $983.71M |
| Net Income (Most Recent Fiscal Year) | $-545.06M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.55 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -55.20% |
| Net Margin (Trailing 12 Months) | -55.41% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -32.63% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.67 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 8.14 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-6.04 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.44 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.41 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.53 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 139.95M |
| Free Float | 138.69M |
| Market Capitalization | $544.42M |
| Average Volume (Last 20 Days) | 3.65M |
| Beta (Past 60 Months) | 1.59 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 53.04% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |